
IRIX — IRIDEX Corporation
NASDAQ · Healthcare · Medical Devices
$0.72
-$0.01 (-1.21%)
IRIDEX Corporation (IRIX) is a medical devices company listed on NASDAQ. It is led by Patrick Mercer, based in 1212 Terra Bella Avenue, Mountain View, CA, United States, 94043, with about 93 employees. IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. In addition, it offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform transscleral laser therapy; G-Probe and G-Probe Illuminate, which are used in procedures to treat uncontrolled and refractory glaucoma; and EndoProbe family of products that are used for endophotocoagulation. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics through direct and independent sales force in the United States, as well as through independent distributors internationally. It operates in the United States, Europe, the Middle East, Africa, the Asia/Pacific region, and the Americas. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.
Latest reported IRIX revenue for 2026-07-04 was $12.6M. Net income was -$1.3M. Revenue was down 48.4% from 2026-07-04 to 2026-07-04. IRIX currently screens at market cap $19.0M.
Use this IRIX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the IRIX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the IRIX SEC filings page. Lician reads the product cache first so this HTML stays unique to IRIDEX Corporation even when a live quote feed is slow.
About IRIDEX Corporation
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. In addition, it offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform transscleral laser therapy; G-Probe and G-Probe Illuminate, which are used in procedures to treat uncontrolled and refractory glaucoma; and EndoProbe family of products that are used for endophotocoagulation. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics through direct and independent sales force in the United States, as well as through independent distributors internationally. It operates in the United States, Europe, the Middle East, Africa, the Asia/Pacific region, and the Americas. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.
IRIX Key Statistics
Market Cap
$18.97M
Volume
102,984
Previous Close
$0.75
Day Range
$0.72 – $0.76
EPS
-$0.26
Revenue
$52.67M
Net Income
-$4.44M
Gross Profit
$19.23M
Free Cash Flow
-$1.97M
Revenue Growth
+8.2%
Profit Margin
-8.4%
Debt to Equity
0.00
Employees
93
IRIX Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2026 | FY2024 |
|---|---|---|
| Revenue | $52.67M | $48.67M |
| Cost of Revenue | $33.45M | $29.17M |
| Gross Profit | $19.23M | $19.50M |
| Operating Income | -$2.57M | -$8.30M |
| Net Income | -$4.44M | -$8.91M |
| EPS (Diluted) | -$0.26 | -$0.54 |
Total Assets
$29.15M
Total Debt
$0.00
Shareholders' Equity
$4.92M
Cash & Equivalents
$6.03M
Operating Cash Flow
-$2.12M
Free Cash Flow
-$1.97M
IRIDEX Corporation Company Information
- CEO, President & Director
- Patrick Mercer
- Headquarters
- 1212 Terra Bella Avenue, Mountain View, CA, United States, 94043
- Website
- www.iridex.com
- Phone
- 650 940 4700
- IPO / Founded
- 1996-02-15
- Sector
- Healthcare
- Industry
- Medical Devices